CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Pembrolizumab was randomly given to 496 patients, while a placebo was given to 498. The estimated percentage of patients still alive at 24 months was 96.6% in the pembrolizumab group and 93.5% in the placebo group. Pembrolizumab therapy was associated with a significantly longer disease-free survival than placebo, and there were no fatalities brought on by the treatment.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
